Bp Plc Maintains Stake in Humana Inc. (NYSE:HUM)

BP PLC continued to hold its position in shares of Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 18,000 shares of the insurance provider’s stock at the end of the second quarter. BP PLC’s holdings in Humana were worth $4,329,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Advisor Partners LLC boosted its stake in Humana by 11.3% in the second quarter. Advisor Partners LLC now owns 3,341 shares of the insurance provider’s stock valued at $804,000 after buying an additional 339 shares in the last quarter. Pictet Asset Management Ltd. boosted its stake in Humana by 15.7% in the second quarter. Pictet Asset Management Ltd. now owns 167,822 shares of the insurance provider’s stock valued at $38,979,000 after buying an additional 22,773 shares in the last quarter. IFP Advisors Inc boosted its stake in Humana by 48.8% in the second quarter. IFP Advisors Inc now owns 3,634 shares of the insurance provider’s stock valued at $874,000 after buying an additional 1,191 shares in the last quarter. Korea Investment CORP boosted its stake in shares of Humana by 191.9% in the second quarter. Korea Investment CORP now owns 192,127 shares of the insurance provider’s stock valued at $46,230,000 after buying an additional 126,312 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of Humana by 47.1% in the second quarter. Candriam Luxembourg S.C.A. now owns 103,000 shares of the insurance provider’s stock valued at $24,785,000 after buying an additional 32,999 shares during the period. 99.13% of the stock is owned by institutional investors.

Humana Inc. (HUM) opened at 247.28 on Friday. The company has a market cap of $35.74 billion, a P/E ratio of 20.34 and a beta of 0.91. The company has a 50-day moving average of $241.05 and a 200 day moving average of $224.57. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $255.27.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the company earned $2.30 EPS. On average, equities analysts forecast that Humana Inc. will post $11.55 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is presently 13.06%.

ILLEGAL ACTIVITY NOTICE: “Bp Plc Maintains Stake in Humana Inc. (NYSE:HUM)” was originally reported by BNB Daily and is owned by of BNB Daily. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/humana-inc-nysehum-position-held-by-bp-plc-updated.html.

HUM has been the topic of several analyst reports. UBS AG reissued a “neutral” rating and set a $250.00 price target (up from $237.00) on shares of Humana in a research report on Wednesday, August 9th. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Monday, April 24th. Cowen and Company reissued a “buy” rating and set a $230.00 price target on shares of Humana in a research report on Friday, July 14th. BidaskClub raised shares of Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $223.00 target price (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Humana presently has an average rating of “Hold” and an average price target of $244.35.

In other news, VP Heidi S. Margulis sold 1,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. Insiders have sold a total of 41,406 shares of company stock worth $10,355,086 in the last three months. Corporate insiders own 0.80% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply